A Randomized, Open, Single-dose, 2x2 Crossover Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics After Co-administration of A51R1 and A51R2 or Administration of AJU-A51 in Healthy Volunteers Under Fasting Conditions
Latest Information Update: 30 Jul 2021
At a glance
- Drugs Dapagliflozin/linagliptin (Primary) ; Dapagliflozin; Linagliptin
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors AJU Pharm
- 30 Jul 2021 New trial record